Filgotinib: Clinical Trials

14 trials of Filgotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 3 terminated, 1 recruiting. 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 214Completed 10, Terminated 3, Recruiting 1

Follow Filgotinib: new trials by email Literature Review of Filgotinib trials Research Report on Filgotinib

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Filgotinib - Behcet's Disease, Idiopathic Inflammatory Myopathies
Phase 2RecruitingUMC Utrecht602024-03-122026-05-12
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
Filgotinib, Placebo, Standard of Care - Rheumatoid Arthritis, Psoriatic Arthritis
Phase 2CompletedLakefront Biotherapeutics NV1092019-05-282024-04-30
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
Filgotinib, Lanraplenib, Filgotinib placebo - Lupus Membranous Nephropathy
Phase 2CompletedGilead Sciences92017-10-062020-05-18
An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.
filgotinib - Psoriatic Arthritis
Phase 2TerminatedLakefront Biotherapeutics NV1222017-07-262022-04-21
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
Filgotinib, Placebo to match filgotinib, Prednisone - Noninfectious Uveitis
Phase 2TerminatedGilead Sciences742017-07-262022-01-21
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
Filgotinib, Placebo, Standard of Care - Inflammatory Bowel Disease
Phase 2TerminatedLakefront Biotherapeutics NV1392017-07-112024-10-09
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Lanraplenib, Filgotinib, Lanraplenib placebo - Cutaneous Lupus Erythematosus
Phase 2CompletedGilead Sciences472017-05-242020-06-09
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
Lanraplenib, Filgotinib, Tirabrutinib - Sjogren's Syndrome
Phase 2CompletedGilead Sciences1522017-05-012020-10-23
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Filgotinib, Placebo to match filgotinib - Small Bowel Crohn's Disease
Phase 2CompletedGilead Sciences782017-04-112021-08-23
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
Filgotinib, Placebo to match filgotinib - Fistulizing Crohn's Disease
Phase 2CompletedGilead Sciences572017-04-062022-04-08
A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis
filgotinib, Placebo Oral Tablet - Psoriatic Arthritis
Phase 2CompletedLakefront Biotherapeutics NV1312017-03-092018-04-23
A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis
filgotinib, Placebo Oral Tablet - Ankylosing Spondylitis
Phase 2CompletedLakefront Biotherapeutics NV1162017-03-072018-08-13
Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate
GS-9876, Filgotinib, GS-9876 placebo - Rheumatoid Arthritis
Phase 2CompletedGilead Sciences832016-09-212018-09-19
Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
Filgotinib - Rheumatoid Arthritis
Phase 2CompletedLakefront Biotherapeutics NV7392014-02-252024-06-04

Conditions studied

Arthritis, Psoriatic (3)  ·  Arthritis, Rheumatoid (3)  ·  Spondylitis, Ankylosing (2)  ·  Behcet Syndrome (1)  ·  Immunoglobulin G4-Related Disease (1)  ·  Inflammatory Bowel Diseases (1)  ·  Lupus Erythematosus, Cutaneous (1)  ·  Myositis (1)  ·  Sjogren's Syndrome (1)

Sponsors

Gilead Sciences (7)  ·  Lakefront Biotherapeutics NV (6)  ·  UMC Utrecht (1)

Countries

United States (9)  ·  Poland (8)  ·  Ukraine (8)  ·  Czechia (7)  ·  Spain (7)  ·  Belgium (6)  ·  Bulgaria (6)  ·  Germany (5)  ·  United Kingdom (5)  ·  Canada (4)  ·  Estonia (4)  ·  Australia (3)  ·  Austria (3)  ·  France (3)  ·  Hungary (3)

Top investigators

Pille Harrison, MD, DPhil, MRCP (UK) (2)  ·  Jaap M van Laar, Prof. dr. (1)  ·  Vijay Rajendran, MD (1)

Results publications

PMID 35614292, PMID 37137672, PMID 30360969, PMID 30360970, PMID 31624837, PMID 33177349, PMID 33380521, PMID 33526618, PMID 34352069, PMID 34498056, PMID 34647992, PMID 35377447, PMID 36205910, PMID 37172783, PMID 37747626, PMID 37945284, PMID 38366672, PMID 39023880, PMID 39884731, PMID 39915014

NIH funding

2016 (4), 2017 (3), 2018 (1)